Trabecular Bone Score in Multiple Sclerosis
Completed
- Conditions
- Endocrine System DiseasesNeurologic DisorderMultiple Sclerosis
- Interventions
- Diagnostic Test: sm tbs group
- Registration Number
- NCT05811689
- Lead Sponsor
- IRCCS Centro Neurolesi "Bonino-Pulejo"
- Brief Summary
Assess bone quality in MS patients through TBS and evaluate the potential effects exerted by different drugs used in MS treatment, which may affect BMD and TBS in MS patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- diagnosis of MS according to the latest revision of McDonald's criteria;
- patients with relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (SPMS);
- absence of cortisone therapy for at least 6 months;
Exclusion Criteria
patients already being treated with anti-osteoporotic drugs;
• medical conditions that preclude the execution of the densitometric examination
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description sm tbs group sm tbs group All patients will undergo densitometric examination with dual-energy x-ray absorptiometry (DXA) technique at our Facility.
- Primary Outcome Measures
Name Time Method DXA scanner (Horizon© DXA System) 6 months The DXA scanner (Horizon© DXA System) measures bone mineral content relative to bone area.
- Secondary Outcome Measures
Name Time Method Bone Mineral Density 6 months BMD will be measured in the lumbar spine (L2-L4) and in the right and left femoral neck and trochanter regions.
Trial Locations
- Locations (1)
IRCCS Centro Neurolesi Bonino Pulejo
🇮🇹Messina, Italy